Vericiguat in Combination with Short‐Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE Study
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2574
Abstract: Vericiguat is a soluble guanylate cyclase stimulator indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization in adults with symptomatic chronic HF and ejection fraction less than 45%. Guidelines recommend short‐acting… read more here.
Keywords: patients chronic; vericiguat; coronary syndromes; chronic coronary ... See more keywords
Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
Sign Up to like & getrecommendations! Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14050
Abstract: Treatment response to vericiguat, based on baseline N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) subgroups specified in the protocol, was evaluated in the heart failure (HF) VICTORIA trial population by post hoc analysis of combined lower three… read more here.
Keywords: heart failure; vericiguat; victoria trial; heart ... See more keywords
Effect of Vericiguat on Left Ventricular Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction: The VICTORIA Echocardiographic Substudy.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of heart failure"
DOI: 10.1002/ejhf.2836
Abstract: BACKGROUND Vericiguat significantly reduced the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death in the VICTORIA trial. It is unknown if these outcome benefits are related to reverse left ventricular (LV) remodeling… read more here.
Keywords: structure function; ejection fraction; heart failure; vericiguat ... See more keywords
Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Clinical Pharmacology"
DOI: 10.1007/s00228-020-03023-7
Abstract: Purpose To characterize the safety, pharmacodynamics, and pharmacokinetics (PK) of vericiguat in healthy males. Methods Six phase I studies were conducted in European, Chinese, and Japanese males. Subjects received oral vericiguat as a single dose… read more here.
Keywords: vericiguat tablets; safety pharmacodynamic; six phase; vericiguat ... See more keywords
Pharmacokinetics and mass balance of vericiguat in rats and dogs and distribution in rats
Sign Up to like & getrecommendations! Published in 2022 at "Xenobiotica"
DOI: 10.1080/00498254.2022.2082899
Abstract: Abstract Vericiguat is a soluble guanylate cyclase stimulator. The pharmacokinetics, absorption, metabolism, and excretion properties of vericiguat in rats and dogs and the distribution in rats are reported. [14C]-labelled vericiguat was studied in intact and… read more here.
Keywords: vericiguat; administration; dogs distribution; distribution rats ... See more keywords
Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
Sign Up to like & getrecommendations! Published in 2023 at "Patient preference and adherence"
DOI: 10.2147/ppa.s400403
Abstract: Abstract Heart failure (HF) is a progressive condition with periods of apparent stability and repeated worsening HF events. Over time, unless optimization of HF treatment, worsening HF events become more frequent and patients enter into… read more here.
Keywords: heart failure; vericiguat; role; heart ... See more keywords